plerixafor has been researched along with Carcinoma, Lewis Lung in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Farber, JM; Jacobson, O; Jacobus, JP; Kiesewetter, DO; Szajek, LP; Weiss, ID | 1 |
| Benayoun, L; Bril, R; Gingis-Velitski, S; Kerbel, RS; Man, S; Milsom, C; Munster, M; Shaked, Y; Voloshin, T | 1 |
2 other study(ies) available for plerixafor and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.
Topics: Animals; Benzylamines; Carcinoma, Lewis Lung; Cell Line, Tumor; CHO Cells; Copper Radioisotopes; Cricetinae; Cricetulus; Cyclams; Female; Heterocyclic Compounds; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Molecular Imaging; Neoplasms, Experimental; Ovarian Neoplasms; Positron-Emission Tomography; Radiation Dosage; Radiopharmaceuticals; Receptors, CXCR4; Tissue Distribution; Transfection; Transplantation, Heterologous | 2012 |
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Drug Combinations; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Humans; Immunohistochemistry; Inflammatory Breast Neoplasms; Injections, Intraperitoneal; Matrix Metalloproteinase 2; Mice; Mice, Knockout; Neovascularization, Pathologic; Paclitaxel; Receptors, CXCR4; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |